Skip to main content
    E

    Elicio Therapeutics Inc. (ELTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.43
    -0.05 (-3.38%)

    Market Cap: $42.46M

    Last updated: Nov 17, 2026 at 4:29 PM ET

    Elicio Therapeutics Inc. (ELTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Elicio Therapeutics (ELTX) has a market cap of $42.46M and an enterprise value of $21.20M. Its share count is up 57.51% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 50.08% below the market cap, as cash exceeds debt.

    Market Cap$42.46M
    Enterprise Value$21.20M
    Latest price (Nov 17, 2026)$1.43

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 36.62% in the quarter ended Sep 30, 2026 and grew 39.13% a year over 2 years.

    Shares Outstanding26.29M
    Shares Change (YoY)+57.51%
    Shares Change (QoQ)+36.62%
    Share Count Growth (2Y CAGR)+39.13%

    Price Statistics

    The stock is down 83.95% over 52 weeks and trades 19.21% below its 50-day average.

    Beta (1Y)0.32
    52-Week Change-83.95%
    1-Month Change-7.74%
    3-Month Change-54.31%
    6-Month Change-84.41%
    5-Year Change-95.97%
    Total Return (1Y)-83.95%
    Total Return (3Y CAGR)-37.68%
    Total Return (5Y CAGR)-49.01%
    Return vs SPY (1Y)-94.87%
    Max Drawdown (1Y)-90.57%
    Max Drawdown (3Y)-90.57%
    Sharpe Ratio (1Y)-1.02
    Correlation with SPY (1Y)0.02
    50-Day Average$1.77
    200-Day Average$6.39
    52-Week Range$1.25 to $16.00
    RSI (14 Days)37.4
    Average Volume (20 Days)335.97K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.43x current liabilities, and total debt is 0.51x shareholder equity.

    Current Ratio3.43x
    Quick Ratio3.43x
    Debt / Equity0.51x
    Interest Coverage-22.24x

    Returns and Efficiency

    Return on invested capital is -96.64% and return on equity is -189.58% over the last 12 months.

    Return on Equity (ROE)-189.58%
    Return on Assets (ROA)-90.25%
    Return on Invested Capital (ROIC)-96.64%
    Return on Capital Employed (ROCE)-117.46%

    Scores

    ELTX has a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$286.00K
    Operating Income-$38.33M
    Pretax Income-$35.68M
    Net Income-$35.74M
    EBITDA-$33.29M
    EBIT-$34.85M
    Reported EPS (TTM)-$1.87

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 47.60% of the $39.60M in total assets.

    Cash and Equivalents$30.90M
    Total Debt$9.63M
    Net Cash$21.27M
    Net Cash Per Share$0.81
    Working Capital$24.11M
    Shareholder Equity$18.85M
    Book Value Per Share$0.72
    Total Assets$39.60M
    Total Liabilities$20.75M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$36.97M
    FCF Per Share-$1.37
    Depreciation and Amortization$1.55M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-69.98%
    Tangible Book Per Share Growth (2Y CAGR)-69.98%

    Revenue and profit by year

    Dividends and Yields

    ELTX does not pay a dividend.

    Buyback Yield-125.18%
    Shareholder Yield-125.18%

    Stock Splits

    The last split was a 1-for-10 reverse split on Jun 2, 2023.

    Last Split DateJun 2, 2023
    Split TypeReverse split
    Split Ratio1:10

    Peer Position

    Against 5 similar companies, ELTX has the 3rd highest ROIC.

    ROIC-96.64% vs -109.01% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -32.90% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About ELTX

    What is ELTX's market cap?

    Elicio Therapeutics has a market cap of $42.46M. Its enterprise value, which adds debt and subtracts cash, is $21.20M.

    How many shares of ELTX are outstanding?

    Elicio Therapeutics has 26.29M shares outstanding. The count is up 57.51% from a year earlier.

    Does ELTX pay a dividend?

    No. Elicio Therapeutics does not pay a dividend.

    How much debt does ELTX have?

    Elicio Therapeutics has $9.63M of total debt and $30.90M of cash and equivalents, a net cash position of $21.27M.